0001209191-17-024862.txt : 20170404 0001209191-17-024862.hdr.sgml : 20170404 20170404164056 ACCESSION NUMBER: 0001209191-17-024862 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170404 DATE AS OF CHANGE: 20170404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cidara Therapeutics, Inc. CENTRAL INDEX KEY: 0001610618 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461537286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-752-6170 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: K2 THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Forrest Kevin CENTRAL INDEX KEY: 0001638943 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36912 FILM NUMBER: 17738906 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-03-31 0 0001610618 Cidara Therapeutics, Inc. CDTX 0001638943 Forrest Kevin 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 0 1 0 0 Chief Scientific Officer Common Stock 2017-03-31 4 P 0 12500 7.75 A 72354 D Employee Stock Option (right to buy) 7.80 2017-03-31 4 A 0 60000 0.00 A 2027-03-30 Common Stock 60000 60000 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.875, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Includes 1,601 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 18, 2016. The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2017. /s/ Marc Wilson, Attorney-in-fact 2017-04-04